JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Intravenous immunoglobulin treatment in laryngeal pemphigoid.

We report a 29-year-old white woman who presented with oral involvement and subsequently developed severe and extensive laryngeal involvement with mucous membrane pemphigoid. She could not tolerate systemic corticosteroids due to side-effects. Dapsone improved only the oral disease, but the laryngeal disease remained active and progressive. She refused immunosuppressive agents, because she wanted to conceive. The acute severe widespread laryngeal pemphigoid was accompanied by severe relentless coughing and dysphonia. The patient was treated with intravenous immunoglobulin (IVIg) as monotherapy, which led to complete resolution of the symptoms and the laryngeal lesions, as seen on repeated direct laryngoscopies. The normal anatomy and function of the larynx was restored, and scarring did not occur. The patient did not develop any side-effects to the IVIg treatment, which led to disease remission. While on IVIg treatment, she delivered a healthy child. She remained in remission after 5 years of follow-up.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app